Overview

Management of Ovarian Hyperstimulation Syndrome as a State of Defective Mineralocorticoid Response

Status:
Completed
Trial end date:
2020-02-29
Target enrollment:
Participant gender:
Summary
lines of evidence that support nature of ovarian hyperstimulation syndrome (OHSS) as "defective mineralocorticoid response" are cited, our hypothesis is tested clinically in both prophylaxis against and treatment of OHSS.
Phase:
Phase 2
Details
Lead Sponsor:
Ganin Fertility Center
Treatments:
Bromocriptine
Fludrocortisone